^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Malignant Pleural Mesothelioma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Respirol Case Rep
    Title:

    Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1

    Published date:
    02/14/2020
    Excerpt:
    We report herein a case of sarcomatoid malignant pleural mesothelioma (MPM) with high PD-L1 expression...After the nivolumab treatment, CT showed a significant reduction in pleural tumours with a marked improvement in symptoms.
    DOI:
    10.1002/rcr2.536